[print friendly]

Search Type: drug or dietary supplement name
Search Term: lovastatin (MEVACOR)

• gemfibrozil (LOPID)
  We list this drug as a Do Not Use drug because, unlike for other drugs for high cholesterol, there is no evidence that it decreases the risk of heart disease. It also causes cancer in animals.
• fluvastatin (LESCOL, LESCOL XL)
• rosuvastatin (CRESTOR)
  We list this drug as a Do Not Use drug because it causes kidney, muscle and liver damage.

• Calcium Channel Blocker Drug Interactions [hide all summaries]
  (May 2008)
  This article lists more than 60 prescription drugs that can interact with calcium channel blocking drugs such as amlodipine (NORVASC),diltiazem (CARDIZEM, DILACOR XR TIAZAC)or nifedipine (PROCARDIA)to either cause toxicity or to lessen the effectiveness of the calcium channel blocking drugs. Included in the lists are a number of drugs that we list in Worst Pills, Best Pills as DO NOT USE or LIMITED USE drugs. The article also explains the different kinds of toxicity that can ensue from these interactions.
• FDA and Drug Makers Should Have Warned Public Earlier About Zetia, Vytorin [hide all summaries]
  (March 2008)
  Find out why Worst Pills warned against the use of VYTORIN more than three years ago. Also, learn about new evidence showing that despite the fact that this drug lowers cholesterol, there is no evidence that it prevents heart attacks or strokes (though massive misleading advertising would have you believe otherwise).
• Macrolide Antibiotic Drug Interactions [hide all summaries]
  (February 2008)
  The article discusses the adverse drug interactions between either of two widely-prescribed macrolide antibiotics, erythromycin (as in ERYTHROCIN) and clarithromycin (BIAXIN)and more than 40 other drugs that are listed in a table in the article. It also describes the nature of the adverse interactions that can occur.
• Drug Interactions: Warfarin (COUMADIN) [hide all summaries]
  (December 2007)
  This article explains how to understand the International Normalized Ratio (INR), a test applied to a sample of a patient’s blood to determine how “thin” it is when you are using the blood thinner COUMADIN (warfarin). In addition, the article lists more than 50 drugs or dietary supplements that can interact harmfully with COUMADIN to cause the blood to be too thin (abnormal bleeding) or not thin enough which could result in lessening the effect of COUMADIN in stopping blood clot formation.
• A Review of Ezetimibe (ZETIA) and Ezetimibe with Simvastatin (VYTORIN) For Cholesterol Lowering [hide all summaries]
  (December 2004)
  We are concerned about any new drug but are particularly concerned about the use of ZETIA together with statins.
• Protecting Profits: Amlodipine With Atorvastatin (CADUET) For High Blood Pressure And High Cholesterol [hide all summaries]
  (August 2004)
  We can think of no medical reason why you should be taking Caduet unless you are being treated satisfactorily with doses of amlodipine and atorvastatin that are available as Caduet. If you have not been tried on more effective drugs for high blood pressure such as diuretics or beta-blockers, amlodipine is a poor choice.
• Do Not Use! Rosuvastatin (Crestor) - A New But More Dangerous Cholesterol Lowering 'Statin' Drug [hide all summaries]
  (October 2003)
  Rosuvastatin (CRESTOR) became the sixth cholesterol lowering "statin" drug on the U.S. There is no medical reason for you to be taking rosuvastatin when there are three safer and more effective statins, in terms of reducing cardiovascular events, on the market.

• Letter to FDA shows that Crestor has higher rates of rhabdomyolysis compared to other statins (HRG Publication #1729) [hide all summaries]
  Crestor (rosuvastatin) has 2.8 times the rate of rhabdomyolysis of the second most toxic statin, analysis shows
• Letter to FDA Renewing Call for Crestor to Be Removed From Market. Rate of Kidney Damage in Crestor Patients Is 75 Times Higher Than in Patients Taking Other Cholesterol Drugs (HRG Publication #1710) [hide all summaries]
  Letter to FDA Renewing Call for Crestor to Be Removed From Market. Rate of Kidney Damage in Crestor Patients Is 75 Times Higher Than in Patients Taking Other Cholesterol Drugs (HRG Publication #1710)

• Drug Safety Withdrawals: Who is Responsible for Notifying Patients? [hide all summaries]
  (December 2002)
  The following editorial, by Health Letter Editor Dr. Sidney Wolfe, appeared in the December issue of Pharmacoepidemiology and Drug Safety. Ultimately, the cost for such notification should be borne by the pharmaceutical company making the dangerous drug. Pharmacists and/or physicians, if the latter have record access, should be reimbursed for doing the company’s work. In addition, the FDA should be given new legislative authority to impose mandatory drug recalls with an enforceable withdrawal schedule governing the level and rapidity of recall and patient notification.

SHOW primary search results for lovastatin (MEVACOR)